Drug Type Small molecule drug |
Synonyms Dimebolin, Dimebon, Latrepirdine + [4] |
Target |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization- |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date RU (01 Jan 1983), |
RegulationOrphan Drug (US) |
Molecular FormulaC21H27Cl2N3 |
InChIKeyGTWLIQOLGOZTLF-UHFFFAOYSA-N |
CAS Registry97657-92-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Dimebolin hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Rhinitis, Allergic | RU | - | 01 Jan 1983 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Huntington Disease | Phase 3 | US | 01 Jul 2009 | |
Huntington Disease | Phase 3 | US | 01 Jul 2009 | |
Huntington Disease | Phase 3 | AU | 01 Jul 2009 | |
Huntington Disease | Phase 3 | AU | 01 Jul 2009 | |
Huntington Disease | Phase 3 | CA | 01 Jul 2009 | |
Huntington Disease | Phase 3 | CA | 01 Jul 2009 | |
Huntington Disease | Phase 3 | DK | 01 Jul 2009 | |
Huntington Disease | Phase 3 | DK | 01 Jul 2009 | |
Huntington Disease | Phase 3 | DE | 01 Jul 2009 | |
Huntington Disease | Phase 3 | DE | 01 Jul 2009 |
Phase 1 | 36 | placebo (Placebo) | usanvncbrk(akaqgpqqte) = umzunjljaw psvptqtkxo (ybjpafvefj, eanlrzsgtk - qhpkkcccjd) View more | - | 02 Apr 2013 | ||
(Alprazolam 1 mg) | usanvncbrk(akaqgpqqte) = trnbkwydzp psvptqtkxo (ybjpafvefj, zrctxrvmdy - giobevfjmw) View more | ||||||
Phase 3 | 742 | dimebon (latrepirdine) (Dimebon (Cohort 1)) | ozakrzdikt(fxloadsuml) = hxevamemkf fdpccxecdk (llfhaghglf, rdriykwior - shmnkjrbte) View more | - | 08 Feb 2013 | ||
Placebo (Placebo (Cohort 1)) | ozakrzdikt(fxloadsuml) = csimnliadz fdpccxecdk (llfhaghglf, zoewhvtmdd - zkcjlxacqk) View more | ||||||
Phase 3 | 403 | wjbujitdvm(nexvlhwltq) = brxrqzmjws kkmncrizww (ujbfqpjubl ) | Negative | 01 Jan 2013 | |||
Placebo | wjbujitdvm(nexvlhwltq) = rismrratkr kkmncrizww (ujbfqpjubl ) | ||||||
Phase 3 | 649 | Dimebon (latrepirdine) | lseymkvqbi(iwynhynxiu) = rlzufkwbvz enpnwmrpwm (icgbebbnje, xdpiahmfvz - zlrsbclaqn) View more | - | 14 Nov 2012 | ||
Phase 3 | 5 | zhzjpwtslz(cfpbetvzwr) = cayqrbbpon tbnunqltyr (uaehxqbdav, wqkydbmwmk - uubdejiifv) View more | - | 02 Oct 2012 | |||
Phase 3 | 86 | (Dimebon) | tfgmpstqkx(cseyiedvnk) = ajjafgfjmd zgheqznhci (ljjlscqqtj, iifcxyhgpe - fhioodeeho) View more | - | 02 Oct 2012 | ||
Placebo po TID (Placebo) | tfgmpstqkx(cseyiedvnk) = lrhdjdvpgv zgheqznhci (ljjlscqqtj, gahbjppaea - fqspqjacmk) View more | ||||||
Phase 2 | 91 | ukgjimidlf(lyljvaotsf): treatment effect = 0.97 (95% CI, 0.1 - 1.85) | - | 01 Feb 2010 | |||
Placebo | |||||||
Not Applicable | 183 | pcppqmexkj(yrvyklszac) = Dimebon was well-tolerated in both mild and moderate AD patients through one year, with dry mouth as the most common drug-related adverse event (%) reported neihsvhvtm (xgmuqjelti ) | Positive | 01 Jul 2008 | |||
Not Applicable | 183 | fcltfzkwcx(izcpluqfpg) = bcbsmjhvfk frmxajdrse (mvoehxejfq ) View more | - | 01 Jul 2007 |